Search for: [Abstract = "an University Medical College in Kraków. We enrolled adult patients with clinically stable asthma, defined as no disease exacerbation during six months preceding inclusion into the study. In subsequent publications, we analyzed plasma cFn concentration, plasma Lp\-PLA2 activity and serum H3cit concentration in relation to asthma severity, pulmonary function tests, biomarkers of systemic inflammation, and for the first two publications also plasma activation of coagulation. In the first part of the studies, 164 patients with asthma were enrolled \(articles I and II\). 72 subjects were included in the control group. The next part included 60 asthmatics who underwent bronchoscopy, enabling cellularity and cytokine analysis of bronchoalveolar lavage fluid \(BALF\) \(article III\). 50 subjects were included in the control group \(not undergoing endoscopy\). Control groups were matched according to sex, age, body mass index, and comorbidities. SUMMARY OF RESULTS\: ARTICLE I In asthma, plasma cFn was significantly increased compared to the control group \(4.11 \[3.30\-4.95\] vs. 2.06 \[1.46\-2.59\] µg\/ml\; p<0.001\). Furthermore, in patients it was positively associated with inflammatory markers, i.e. high\-sensitivity C\-reactive protein \(hsCRP\) \(β= 0.24 \[95%CI\: 0.16–0.32\]\) and interleukin\-6 \(β= 0.23 \[95%CI\: 0.15–0.30\]\), while the relationship between cFn and FEV1\/VC was negative \(β= –0"]

Number of results: 1